Basic Information


GTO ID GTC1612
Trial ID NCT02761915
Disease Neuroblastoma
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment 1RG CAR-T cells
Generation2nd
PhasePhase1
Recruitment statusCompleted
TitleA Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Year2016
CountryUnited Kingdom
Company sponsorCancer Research UK
Other ID(s)CRUKD/15/001|2013-004554-17

Clinical Result

Cohort1: dose level 1
Administration route intravenous infusion
Dosage 1E7 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes
Cohort2: dose level 2_Cyclophosphamide
Administration route intravenous infusion
Dosage 1E7 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes
Cohort3: dose level 3_Cyclophosphamide_Fludarabine
Administration route intravenous infusion
Dosage 1E7 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes
Cohort4: dose level 4_Cyclophosphamide_Fludarabine
Administration route intravenous infusion
Dosage 1E8 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes
Cohort5: dose level 5
Administration route intravenous infusion
Dosage 5~10E8 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes

Relationship Graph

Overview of Knowledge Graph